R Squared’s Atara Biotherapeutics ATRA Stock Holding History

R Squared’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-240	Closed	-$3.19K	–	393
2024 Q4	$3.19K	Buy	+240	New	+$2.53K	﹤0.01%	1400

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

R Squared's ATRA Position: Q1 2025 in Review

R Squared sold out of Atara Biotherapeutics (ATRA) in Q1 2025, closing a stake of 240 shares — an estimated $3.19K sold.

R Squared first reported a position in ATRA in Q4 2024 and held it in 1 quarter. The position peaked at $3.19K in Q4 2024. 37 funds tracked by Wall St. Rank hold ATRA as of Q1 2025.

R Squared reported no remaining Atara Biotherapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 240 Atara Biotherapeutics shares in Q1 2025, an estimated $3.19K.
R Squared first reported a position in Atara Biotherapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Atara Biotherapeutics position peaked at $3.19K in Q4 2024.
37 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.